Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Achelois Biopharma Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners across 2 art units. GRIZER, CASSANDRA SENN is the busiest identified examiner, with 1 pending action.
The separate examiner and unit assignments indicate that the matters should be reviewed as distinct prosecution tracks. Counsel can coordinate portfolio objectives while tailoring each response to its assigned examination group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRIZER, CASSANDRA SENN | 1 | 70.0% | +48.0% |
| GURLEY, JAMI MICHELLE | 1 | 54.8% | +14.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560619 | COMPOSITIONS AND METHODS FOR MULTIVALENT SURFACE DISPLAY ON ENVELOPED PARTICLES | GRIZER, CASSANDRA SENN | — |
| 18560623 | IMMUNE CHECKPOINT MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE | GURLEY, JAMI MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560619 | COMPOSITIONS AND METHODS FOR MULTIVALENT SURFACE DISPLAY ON ENVELOPED PARTICLES | GRIZER, CASSANDRA SENN | — |
| 18560623 | IMMUNE CHECKPOINT MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE | GURLEY, JAMI MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560619 | COMPOSITIONS AND METHODS FOR MULTIVALENT SURFACE DISPLAY ON ENVELOPED PARTICLES | GRIZER, CASSANDRA SENN | 1672 | §102§103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18560623 | IMMUNE CHECKPOINT MULTIVALENT PARTICLES COMPOSITIONS AND METHODS OF USE | GURLEY, JAMI MICHELLE | 1647 | §103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAchelois Biopharma Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Cassandra Senn Grizer has the most, with 1 of Achelois Biopharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
